

Steadman 09/970,515

=> d his

(FILE 'HOME' ENTERED AT 15:33:57 ON 16 JUL 2003)

FILE 'REGISTRY' ENTERED AT 15:34:07 ON 16 JUL 2003
L1 3 S SDQAGLTLRLTTPRHKHPEE/SQSP

FILE 'HCAPLUS' ENTERED AT 15:35:49 ON 16 JUL 2003
L2 2 S L1
L3 672 S JNK(3A)INHIBIT?
L4 10857 S D(3A)AMINO(3A)ACID#
L5 1 S L3 AND L4
L6 11014 S PEPTIDE#(3A)INHIBITOR?
L7 18 S L6 (L)JNK
L8 1 S L7 AND L4
L9 0 S D(3A)ISOMER? AND L3
L10 0 S D(3A)ISOMER? AND JNK
L11 1 S L5 OR L8
L12 1 S L2 NOT L11

=> d ibib abs l11

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2003:454824 HCAPLUS
DOCUMENT NUMBER: 139:30852
TITLE: Cell-permeable peptide inhibitors
of the JNK signal transduction pathway
INVENTOR(S): Bonny, Christophe
PATENT ASSIGNEE(S): Switz.
SOURCE: U.S. Pat. Appl. Publ., 39 pp., Cont.-in-part of U.S.
Ser. No. 503,954.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003108539	A1	20030612	US 2002-165250	20020607
PRIORITY APPLN. INFO.:			US 2000-503954	A2 20000214
			US 2002-347062P	P 20020109

AB The invention provides cell-permeable peptides that bind to **JNK** proteins and **inhibit JNK**-mediated effects in **JNK**-expressing cells. The peptides, referred to herein as **JNK peptide inhibitors**, decrease the downstream cell-proliferative effects of c-Jun amino terminal kinase (**JNK**). The **JNK inhibitor peptides** can be present as polymers of **L-amino acids** or **D-amino acids**. The invention includes a method of treating a pathophysiol. assocd. with activation of **JNK** in a cell or cells. The invention further provides a method of preventing or treating hearing loss in a subject. The method includes administering to the subject a cell-permeable bioactive peptide which prevents damage to the hair cell stereocilia, hair cell apoptosis, or neuronal apoptosis. The invention also contemplates a method of inhibiting pancreatic islet cell death, where the method includes contacting a pancreatic islet cell with a cell-permeable bioactive peptide such that pancreatic cell death is inhibited.

=> d ibib abs 112

L12 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:284095 HCAPLUS
 DOCUMENT NUMBER: 134:305311
 TITLE: Cell-permeable peptide inhibitors of the JNK signal transduction pathway and their therapeutic use
 INVENTOR(S): Bonny, Christophe
 PATENT ASSIGNEE(S): University of Lausanne, Switz.
 SOURCE: PCT Int. Appl., 50 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001027268	A2	20010419	WO 2000-IB1538	20001012
WO 2001027268	A3	20011122		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1303600	A2	20030423	EP 2000-969730	20001012
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
US 2002127676	A1	20020912	US 2001-970515	20011003
PRIORITY APPLN. INFO.:			US 1999-158774P	P 19991012
			US 2000-503954	A2 20000214
			WO 2000-IB1538	W 20001012

AB The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells. The invention is based on the discovery that islet-brain (IB) 1 and 2 proteins can be used to inhibit signaling mediated by JNK (a member of the stress-activated group of mitogen-activated protein kinases or MAPKs) and thus prevent interleukin (IL)-1. β -induced pancreatic . β .-cell death. Bioactive cell-permeable peptide inhibitors of JNK are engineered by linking the minimal 20-amino acid inhibitory domains of the IB proteins to the 10-amino acid HIV-TAT sequence contg. nuclear localization signal peptide. Kinase assays indicate that the inhibitors block activation of the transcription factor c-Jun by JNK. These bioactive cell-permeable peptides can be used as potent pharmacol. compds. that decrease intracellular JNK signaling and confer long-term protection to pancreatic . β .-cells from IL-1. β -induced apoptosis.